Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sponsor

ADC Therapeutics S.A. (Industry)

Overall Status

No longer available

CT.gov ID

NCT04705454

Collaborator

(none)

Study Details

Study Description

Brief Summary

The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials. ADC Therapeutics will evaluate patients for approval into the program.

Condition or Disease	Intervention/Treatment	Phase
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)	Biological: Loncastuximab Tesirine

Study Design

Study Type:

Expanded Access

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Inclusion Criteria:

Male or female patient aged 18 years or older
Pathologic diagnosis of DLBCL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials
Women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least six months after the last dose of loncastuximab tesirine. Men with female partners who are of childbearing potential must agree that they will use a highly effective method of contraception from the time of giving informed consent until at least six months after the patient receives his last dose of loncastuximab tesirine

Exclusion Criteria:

Known history of hypersensitivity to or positive serum human Anti-Drug Antibodies to loncastuximab tesirine
Total bilirubin >1.5 x upper limit of normal (ULN)
Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that ADCT Head of Medical Affairs and/or designee, and treating physician agree and document should not be exclusionary
Autologous Stem Cell Transplantation (SCT) within 30 days prior to start of loncastuximab tesirine
Allogeneic SCT within 60 days prior to start of loncastuximab tesirine
Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
Lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease
Breastfeeding or pregnant
Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14 days prior to starting loncastuximab tesirine, except shorter if approved by ADCT
Use of any other experimental medication within 14 days prior to starting loncastuximab tesirine
Any other significant medical illness, abnormality, or condition that would, in the treating physician's judgment, make the patient inappropriate to receive loncastuximab tesirine or put the patient at risk